Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Amur Minerals ( (GB:CRTX) ) just unveiled an announcement.
CRISM Therapeutics has reported progress on its Phase 2 clinical trial of irinotecan-ChemoSeed in glioblastoma, confirming that US-based ProMed Pharma has successfully manufactured the first clinical batch of ChemoSeed to current Good Manufacturing Practice standards. The batch will now undergo sterilisation and release testing before being deployed in the study, marking a key operational milestone for the programme.
The company is working with contract research organisation Aixial and the first clinical trial site to finalise site activation steps prior to patient dosing, but has extended its guidance for first patient dosing to the first half of 2026 due to uncertainty over exact timing. The update signals that while timelines have shifted, CRISM remains close to trial initiation, a critical step for validating its implantable chemotherapy platform and potentially strengthening its position in the oncology drug delivery market.
The most recent analyst rating on (GB:CRTX) stock is a Hold with a £12.50 price target. To see the full list of analyst forecasts on Amur Minerals stock, see the GB:CRTX Stock Forecast page.
Spark’s Take on CRTX Stock
According to Spark, TipRanks’ AI Analyst, CRTX is a Neutral.
The score is held back primarily by weak financial fundamentals (very small revenue with ongoing losses and negative free cash flow), despite improved loss/cash-burn trends and a debt-free balance sheet. Technically, momentum is positive, but the very high RSI suggests near-term overextension. Valuation remains unattractive/unclear due to negative earnings and no indicated dividend support.
To see Spark’s full report on CRTX stock, click here.
More about Amur Minerals
CRISM Therapeutics Corporation is a UK-based, clinical-stage drug delivery company focused on improving cancer treatment for solid tumours through localised and sustained delivery of chemotherapy drugs. Its lead product, ChemoSeed, is designed for implantation directly into tumours or resection margins, including in glioblastoma surgery where it can bypass the blood-brain barrier to deliver therapeutic concentrations of chemotherapy to otherwise hard-to-reach tumour tissue.
Average Trading Volume: 356,329
Technical Sentiment Signal: Buy
Current Market Cap: £6.6M
See more data about CRTX stock on TipRanks’ Stock Analysis page.